Format

Send to

Choose Destination
JAMA Dermatol. 2014 Jul;150(7):748-51. doi: 10.1001/jamadermatol.2014.504.

Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata.

Author information

1
Department of Dermatology, University Hospital of Nice, Nice, France.
2
Department of Dermatology, University Hospital of Nice, Nice, France2Centre de Recherche Clinique (CRC), University Hospital of Nice, Nice, France.
3
Laboratory of Clinical and Experimental Pathology, University Hospital of Nice, Nice, France.
4
Laboratory of Immunology, University Hospital of Nice, Nice, France.
5
Department of Dermatology, University Hospital of Nice, Nice, France5Institut National de la Santé et de la Récherche Médicale (INSERM) U1065, Team 12, Mediterranean Centre of Molecular Medicine, Nice, France.

Abstract

IMPORTANCE:

An impaired inhibitory function of circulating CD4+CD25+ regulatory T (Treg) cells was reported to play a key role in alopecia areata (AA). We report the first use to our knowledge of low-dose interleukin 2 for treating severe AA by promoting the recruitment of Treg cells.

OBSERVATIONS:

We conducted a prospective open pilot study in 5 patients with severe AA resistant to previous systemic treatments. Subcutaneous interleukin 2 (1.5 million IU/d) was administered during 5 days, followed by three 5-day courses of 3 million IU/d at weeks 3, 6, and 9. The primary outcome was the evolution of the Severity of Alopecia Tool (SALT) score, evaluated by 2 independent investigators on standardized photographs. Lesional skin biopsy specimens and peripheral blood lymphocyte phenotype were analyzed. The median SALT score went from 82 (range, 63-100) at baseline to 69 (range, 28-100) at 6 months. Immunochemical analysis revealed the appearance or a notable increase in Treg cell count in 4 of 5 patients at the end of the treatment compared with baseline. No serious adverse event was reported.

CONCLUSIONS AND RELEVANCE:

The partial regrowth achieved in 4 of 5 patients and the recruitment of Treg cells in lesional skin support the interest of promoting Treg cells for treating AA. Further investigations are now required to confirm and to optimize the design in order to enhance the Treg cell response.

TRIAL REGISTRATION:

clinicaltrials.gov Identifier: NCT01840046.

PMID:
24872229
DOI:
10.1001/jamadermatol.2014.504
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center